Abstract: Disclosed herein are methods in which an individual with multiple sclerosis (MS) can be classified into one of six subject groups, each subject group predictive for the patient's responsiveness to an interferon-? (IFN-?) therapy. The individual with MS can be classified according to the individual's serum marker levels, e.g., at baseline or following treatment with therapy. Depending on the classification, the individual with MS can be treated with standard therapies (e.g. IFN-?) or one or more alternative therapies with or without IFN-?.

Abstract: Provided herein are methods and compositions for treating inflammatory diseases by administering to the subject an effective dose of an anti-?5 agent.

Abstract: The instant disclosure provides replacement gene tolerizing vectors and methods of using such vectors for treating individuals receiving gene therapy for muscular dystrophy, e.g., Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), etc. Aspects of the methods include administering to the individual, in need thereof, an effective amount of a gene therapy tolerizing vaccine composition that includes a replacement gene tolerizing vector to reduce one or more symptoms of a subject's immune response to gene therapy treatment for muscular dystrophy and/or improve the efficacy of the gene therapy. Compositions and kits for practicing the methods of the disclosure are also provided.

Abstract: Methods and formulations to target and activate B-1a lymphocytes and/or macrophages are described. The methods and formulations can be delivered to the respiratory tract to target B-1a lymphocytes and/or macrophages in the pleural cavity. Conditions with inflammatory or autoimmune components can be treated. B-1a lymphocytes and/or macrophages can be targeted and activated using fibrils or fibril-forming peptides.

Abstract: Methods of treatment of Huntington's disease or its symptoms, with PPAR? agonists, and in particular, the compound of formula (I) known as INT131:

Abstract: The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.

Abstract: The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines.

Abstract: The instant disclosure provides aquaporin DNA tolerizing vaccines and methods of using such vaccines for treating individuals having neuromyelitis optica (NMO) and NMO spectrum disorders. Aspects of the methods include administering to the individual, in need thereof, an effective amount of an aquaporin DNA tolerizing vaccine to reduce one or more symptoms of NMO or an NMO spectrum disorder. Compositions and kits for practicing the methods of the disclosure are also provided.

Abstract: Provided herein are methods and compositions for treating inflammatory diseases by administering to the subject an effective dose on an anti-?5 agent.

Abstract: The instant disclosure provides aquaporin DNA tolerizing vaccines and methods of using such vaccines for treating individuals having neuromyelitis optica (NMO) and NMO spectrum disorders. Aspects of the methods include administering to the individual, in need thereof, an effective amount of an aquaporin DNA tolerizing vaccine to reduce one or more symptoms of NMO or an NMO spectrum disorder. Compositions and kits for practicing the methods of the disclosure are also provided.

Abstract: Disclosed herein are methods in which an individual with multiple sclerosis (MS) can be classified into one of six subject groups, each subject group predictive for the patient's responsiveness to an interferon-? (IFN-?) therapy. The individual with MS can be classified according to the individual's serum marker levels, e.g., at baseline or following treatment with therapy. Depending on the classification, the individual with MS can be treated with standard therapies (e.g. IFN-?) or one or more alternative therapies with or without IFN-?.

Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of specific peptides derived from HSPB5, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.

Abstract: The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines.

Abstract: Provided herein are methods and compositions for treating demyelinating inflammatory diseases by administering to the subject an effective dose on an FXR agonist.

Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an amyloid beta peptide, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.

Abstract: The instant disclosure provides replacement gene tolerizing vectors and methods of using such vectors for treating individuals receiving gene therapy for muscular dystrophy, e.g., Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), etc. Aspects of the methods include administering to the individual, in need thereof, an effective amount of a gene therapy tolerizing vaccine composition that includes a replacement gene tolerizing vector to reduce one or more symptoms of a subject's immune response to gene therapy treatment for muscular dystrophy and/or improve the efficacy of the gene therapy. Compositions and kits for practicing the methods of the disclosure are also provided.

Abstract: The instant disclosure provides aquaporin DNA tolerizing vaccines and methods of using such vaccines for treating individuals having neuromyelitis optica (NMO) and NMO spectrum disorders. Aspects of the methods include administering to the individual, in need thereof, an effective amount of an aquaporin DNA tolerizing vaccine to reduce one or more symptoms of NMO or an NMO spectrum disorder. Compositions and kits for practicing the methods of the disclosure are also provided.

Abstract: Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Additionally, serum autoantibody and/or cytokine signature patterns can be utilized to monitor responses to therapy. Assessment of this signature pattern of autoantibodies and/or cytokines in a patient thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is rheumatoid arthritis.

Abstract: The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.

Abstract: This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject and (ii) a pharmaceutically acceptable carrier. This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier.